Literature DB >> 25165153

The mouse idd2 locus is linked to the proportion of immunoregulatory double-negative T cells, a trait associated with autoimmune diabetes resistance.

Roxanne Collin1, Véronique Dugas1, Adam-Nicolas Pelletier1, Geneviève Chabot-Roy2, Sylvie Lesage3.   

Abstract

Autoimmune diseases result from a break in immune tolerance. Various mechanisms of peripheral tolerance can protect against autoimmunity, including immunoregulatory CD4(-)CD8(-) double-negative (DN) T cells. Indeed, we have previously shown that diabetes-prone mouse strains exhibit a low proportion of DN T cells relative to that of diabetes-resistant mice, and that a single autologous transfer of DN T cells can impede autoimmune diabetes development, at least in the 3A9 TCR transgenic setting. In this study, we aim to understand the genetic basis for the difference in DN T cell proportion between diabetes-resistant and diabetes-prone mice. We thus perform an unbiased linkage analysis in 3A9 TCR F2 (NOD.H2(k) × B10.BR) mice and reveal that a locus on chromosome 9, which coincides with Idd2, is linked to the proportion of DN T cells in the lymph nodes. We generate two NOD.H2(k).B10-Chr9 congenic mouse strains and validate the role of this genetic interval in defining the proportion of DN T cells. Moreover, we find that the increased proportion of DN T cells in lymphoid organs is associated with a decrease in both diabetes incidence and serum IgG Ab levels. Together, the data suggest that Idd2 is linked to DN T cell proportion and that a physiological increase in DN T cell number may be sufficient to confer resistance to autoimmune diabetes. Altogether, these findings could help identify new candidate genes for the development of therapeutic avenues aimed at modulating DN T cell number for the prevention of autoimmune diseases.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25165153     DOI: 10.4049/jimmunol.1400189

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Genetic interaction between two insulin-dependent diabetes susceptibility loci, Idd2 and Idd13, in determining immunoregulatory DN T cell proportion.

Authors:  Roxanne Collin; Kathy Doyon; Victor Mullins-Dansereau; Martin Karam; Geneviève Chabot-Roy; Erin E Hillhouse; Alexandre Orthwein; Sylvie Lesage
Journal:  Immunogenetics       Date:  2018-04-25       Impact factor: 2.846

2.  An orthologous non-MHC locus in rats and mice is linked to CD4+ and CD8+ T-cell proportion.

Authors:  D Franckaert; R Collin; J Dooley; R H Wallis; P Poussier; A Liston; E E Hillhouse; S Lesage
Journal:  Genes Immun       Date:  2017-05-25       Impact factor: 2.676

3.  Genes Outside the Major Histocompatibility Complex Locus Are Linked to the Development of Thyroid Autoantibodies and Thyroiditis in NOD.H2h4 Mice.

Authors:  Sandra M McLachlan; Sylvie Lesage; Roxanne Collin; Bianca Banuelos; Holly A Aliesky; Basil Rapoport
Journal:  Endocrinology       Date:  2017-04-01       Impact factor: 4.736

4.  Evidence of genetic epistasis in autoimmune diabetes susceptibility revealed by mouse congenic sublines.

Authors:  Roxanne Collin; Véronique Dugas; Adam-Nicolas Pelletier; Geneviève Chabot-Roy; Sylvie Lesage
Journal:  Immunogenetics       Date:  2021-03-23       Impact factor: 2.846

5.  TCR transgenic mice reveal the impact of type 1 diabetes loci on early and late disease checkpoints.

Authors:  Erin E Hillhouse; Adrian Liston; Roxanne Collin; Eric Desautels; Christopher C Goodnow; Sylvie Lesage
Journal:  Immunol Cell Biol       Date:  2016-04-05       Impact factor: 5.126

6.  Human Double-Negative Regulatory T-Cells Induce a Metabolic and Functional Switch in Effector T-Cells by Suppressing mTOR Activity.

Authors:  Tabea Haug; Michael Aigner; Moritz M Peuser; Carolin D Strobl; Kai Hildner; Dimitrios Mougiakakos; Heiko Bruns; Andreas Mackensen; Simon Völkl
Journal:  Front Immunol       Date:  2019-04-26       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.